Spectral AI, Inc. (Nasdaq: MDAI) announced on October 23, 2025 that it has priced a $7.6 million equity offering, issuing 4,000,000 shares of common stock at $1.90 per share and accompanying pre‑funded warrants with an exercise price of $2.51 per share.
The transaction provides the company with additional growth capital to support the continued expansion and development of its DeepView® System, the AI‑driven predictive diagnostics platform for wound care. The capital will be used to accelerate clinical validation, broaden product indications, and prepare for commercial readiness in 2026.
Spectral AI also emphasized its ongoing commitment to the BARDA Project BioShield contract, noting that the new funding will help sustain its current government program while advancing its broader market strategy. The infusion strengthens the company’s cash position and provides a financial buffer for future regulatory and commercialization milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.